
Strong Accuracy and Outcomes Across All Major Indicators
- A demonstrated 8.5% Mean Absolute Relative Difference (MARD)1
- Fluorescence-based technology unaffected by ascorbic acid and acetaminophen2
- Excellent accuracy in the 2.2-3.3 mmol/L hypoglycemic range (86.5% within 15/15 YSI)3
- Sensor adherence of 23+ hours per day4,5
- A clinically meaningful HbA1c reduction across major studies3-5
For more information on Eversense’s safety and performance, contact us to get a copy of our Outcomes Summary.
1 Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206. 2 Sensor Chemical Interference Screen Summary Report. Senseonics internal reporting, USA, July 2015. 3 Eversense FDA Summary of Safety and Effectiveness Data (SSED) 4 Data on file. Senseonics 2019. 5 PRECISE Supplement. Data on file. Senseonics 2018. 6 Lind M, Diabetes Metab Syndr. 2008;2(4) 282-293. 7 Kropff, J. PRECISE study. Diabetes Care, 40(1), 63-68.
MKT-001296 Rev1